Review article

PSA Screening for Early Detection of Prostate Cancer

Silvio Altarac orcid.org/0000-0003-4308-0541 ; Josip Juraj Strossmayer University of Osijek, Faculty of Medicine, Osijek, Hrvatska

Abstract

Screening for prostate cancer is a controversial topic with some conflicting issues regarding systematic or opportunistic program. The potential impact of this topic would necessitate the highest level of evidence produced through a systematic literature search of all published trials or cohorts summarized in a meta-analysis and a Cochrane review. Risk-adapted strategy for PSA screening should be individualized with discussing potential risks and benefits. Prerequisite is general good health and at least ten years life expectancy in well-informed patients. PSA screening should begin at 50-years old men or 45-years old with positive family history of prostate cancer. Men with a PSA value higher than 1 ng/ml at 40 years of age, and with a PSA value higher than 2 ng/ml at 60 years of age, need at least two years follow-up interval. New biological markers such as PCA 3, kallikreines or TMPRSS2-Erg fusion incorporated in the Phi or 4K score tests show additional sensitivity and specificity comparing to PSA test, therefore, avoiding unnecessary biopsies and lowering overdiagnosis.

Keywords

prostate cancer screening

Hrčak ID:

195089

URI

https://hrcak.srce.hr/195089

Publication date:

6.3.2018.

Article data in other languages: croatian

Visits: 1.909 *